Lazard LAZ
-
Lazard downgrades Abiomed on Impella reimbursement concerns
(Reuters) - Shares in medical device maker Abiomed Inc could remain under pressure due to concerns about any possible reimbursement issue with its Impella heart pump, said brokerage Lazard Capital...
-
Time Is Ripe to Put Cash Into These Financials
… requirements. Click here for option prices on HSBC Lazard LAZ Lazard has a storied history that can be traced back to 1848 ..... advisory, restructuring advisory, and asset management. Lazard has offices in over 40 cities across more than 25 countries …
-
Express Scripts Holding's CEO Discusses Q1 2012 Results - Earnings Call Transcript
… Lawrence C. Marsh - Barclays Capital, Research Division Ricky Goldwasser - Morgan Stanley, Research Division Thomas Gallucci - Lazard Capital Markets LLC, Research Division Robert P. Jones - Goldman Sachs Group Inc., Research Division Steven Valiquette …
-
Tenet Healthcare's CEO Discusses Q1 2012 Results - Earnings Call Transcript
… Giacobbe - Crédit Suisse AG, Research Division Kevin M. Fischbeck - BofA Merrill Lynch, Research Division Thomas Gallucci - Lazard Capital Markets LLC, Research Division Adam T. Feinstein - Barclays Capital, Research Division Sheryl R. Skolnick - CRT …
-
Clean Energy Fuels CEO Discusses Q1 2012 Results - Earnings Call Transcript
… and Chief Executive Officer Richard Wheeler - Chief Financial Officer Analysts Rob Brown - Craig-Hallum Graham Mattison – Lazard Capital Markets Eric Stine - Northland Capital Markets Matthew Blair - Macquarie Capital Brian Gamble - Simmons & Company Presentation …
-
Rib-X Pharmaceuticals Looks To Inject Cash Through May 9 IPO
… million from the sale. The deal is expected to come on May 9th and is underwritten by Deutsche Bank Securities, William Blair, Lazard Capital Markets and Needham. Rib-X Pharmaceuticals Is An Emerging Growth Company Rib-X will be classified as an "emerging …
-
Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript
… Stifel Nicolaus Matthew Lowe – J.P. Morgan Chase & Co. David Miller – Biotech Stock Research, L.L.C. Ryan Martins – Lazard Capital Markets Biren Amin – Jefferies Echo He – Maxim Group Presentation Operator Good day, Ladies and Gentlemen, and welcome …
-
Covance's CEO Discusses Q1 2012 Results - Earnings Call Transcript
… First Analysis Securities Corporation, Research Division Garen Sarafian - Citigroup Inc, Research Division Stephen S. Unger - Lazard Capital Markets LLC, Research Division Douglas D. Tsao - Barclays Capital, Research Division Timothy C. Evans - Wells Complete …
-
HCA Holdings' CEO Discusses Q1 2012 Results - Earnings Call Transcript
… Ralph Giacobbe – Credit Suisse Adam Feinstein – Barclays Kevin Fischbeck – Bank of America/Merrill Lynch Tom Gallucci – Lazard Capital Markets AJ Rice – UBS Matthew Borsch – Goldman Sachs Sheryl Skolnick – CRT Capital Group Gary Taylor – Citi Deepak …
-
New Morningstar Analyst Report - Lazard
… compensation ratio over the next year or two. Lazard receives capital market advisory fees ..... stoke demand for restructuring work. Lazard has one of the largest geographic footprints ..... positioned if global M&A accelerates. Lazard has been consistently profitable in the …